Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Core Scientific (CORZ) EBT Margin (2021 - 2026)

Core Scientific has reported EBT Margin over the past 6 years, most recently at 300.74% for Q1 2026.

  • Quarterly results put EBT Margin at 300.74% for Q1 2026, down 102562.0% from a year ago — trailing twelve months through Mar 2026 was 341.4% (down 8065.0% YoY), and the annual figure for FY2025 was 90.29%, up 19111.0%.
  • EBT Margin reached 300.74% in Q1 2026 per CORZ's latest filing, down from 270.87% in the prior quarter.
  • Across five years, EBT Margin topped out at 724.87% in Q1 2025 and bottomed at 1191.23% in Q2 2025.
  • Median EBT Margin over the past 5 years was 220.13% (2022), compared with a mean of 208.33%.
  • The largest annual shift saw EBT Margin skyrocketed 60725bps in 2025 before it plummeted -102562bps in 2026.
  • Over 5 years, EBT Margin stood at 376.36% in 2022, then soared by 63bps to 137.64% in 2023, then plummeted by -123bps to 306.32% in 2024, then surged by 188bps to 270.87% in 2025, then crashed by -211bps to 300.74% in 2026.
  • Business Quant data shows EBT Margin for CORZ at 300.74% in Q1 2026, 270.87% in Q4 2025, and 177.43% in Q3 2025.